SA
Go ProLog In
EWTX
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
8 analysts·Limited coverage
69
Score
7 Buy (88%)0 Hold (0%)1 Sell (12%)
Rating Breakdown
Strong Buy
00%
Buy
788%
Hold
00%
Sell
113%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$25.00
-21.0%
Consensus
$45.50
+43.8%
Bull
$52.00
+64.4%
12-Month Target Range8 analysts
$25.00$45.50$52.00
Current $31.63Consensus
Current Price
$31.63
Upside to Consensus
$13.87

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+536.52%
EPS—
FY2028
Rev+781.46%
EPS—
FY2029
Rev+159.01%
EPS—

Earnings Surprises

Recent Analyst Actions

May 6, 2026Truist Financial
Edgewise Therapeutics price target raised to $52 from $46 at Truist
Target:$52.00
+39.4%from $37.30
Mar 10, 2026Raymond James
Raymond James Reiterates Strong Buy Rating on Edgewise Therapeutics (EWTX): "we expect investor interest to grow"
Target:$46.00
+55.0%from $29.67
Feb 26, 2026Evercore ISI
Edgewise Therapeutics (EWTX) PT Raised to $45 at Evercore ISI
Target:$45.00
+51.7%from $29.66
Feb 26, 2026Stifel Nicolaus
Edgewise Therapeutics (EWTX) PT Raised to $25 at Stifel
Target:$25.00
-16.2%from $29.83
Sep 24, 2025Goldman Sachs
Goldman Sachs assigns Neutral rating to Edgewise Therapeutics
Target:$20.00
+20.6%from $16.59
Mar 7, 2025Scotiabank
Edgewise Therapeutics initiated with an Outperform at Scotiabank
Target:$50.00
+78.5%from $28.01
Dec 5, 2024Truist Financial
Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX), 'have reasons to believe that EWTX's study is not the study in question'
Target:$50.00
+58.4%from $31.57
Oct 11, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
Target:$51.00
+67.5%from $30.45
Sep 20, 2024RBC Capital
Edgewise Therapeutics (EWTX) PT Raised to $42 at RBC Capital
Target:$42.00
+42.4%from $29.50
Sep 19, 2024Leerink Partners
Edgewise Therapeutics (EWTX) PT Raised to $42 at Leerink Partners
Target:$42.00
+42.4%from $29.50
Jul 1, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Edgewise Therapeutics (EWTX)
Target:$48.00
+166.5%from $18.01

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance